Franck Lescure

Biography

 Dr. Franck Lescure, Ph.D., serves as a Partner and Member of Executive Board at Auriga Partners and Auriga IV Bioseeds Fund. He focuses on life sciences investments. Dr. Lescure joined Auriga Partners in April 2004. In 1997, he became a Medical and Marketing Manager of the "Medical Oxygen" international project in the Air Liquide Group. In 2001, Dr. Lescure started and developed a new Air Liquide service offer for controlled air environments, including industrial clean rooms. In January 2003, he entered Crédit Lyonnais Private Equity as an Associate in life sciences venture investment. Dr. Lescure has also worked at PSA Peugeot Citroen as a Consultant. He started his career in Serono Genetics Institute S.A. in 1990 and worked as a Scientist on Therapeutic Applications of short oligonucleotides. Then, as a Project Manager, Dr. Lescure achieved the development of a new generation of the in-parallel DNA synthesizer. He was an Associate of Omnes Capital. Dr. Lescure began his career in Genset, from 1990 to 1995, working on therapeutic applications of oligonucleotides and the development of a new-generation DNA synthesizer. He serves as a Director of MEDIAN Technologies S.A.; and Fab'Entech. Dr. Lescure serves as a Member of Supervisory Board at CYTOO SA. He serves as a Director of Amoeba S.A. He serves as a Member of the Supervisory Board of Pherecydes Pharma SA and Pylote SAS. He served as a Member of Supervisory Board at ERYtech Pharma SA. As a Specialist in life sciences, Dr. Lescure sits on the Board of Directors and/or the Supervisory Board in companies such as Médian, TcLand Expression SA. He served as a Member of the Supervisory Board of TxCell S.A. Dr. Lescure is an alumnus of the Ecole Normale Supérieure. He holds a Ph.D. in Molecular Virology. Dr. Lescure holds an M.B.A. from Collège des Ingénieurs and is a graduate of the Institut Pasteur.

Research Interest

 Therapeutic Applications of short oligonucleotides